Is long-term androgen suppression right for everyone with locally advanced prostate cancer?

The Lancet Oncology

Volumn 11, Issue 11, 2010, Pages 1016-1017

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; TESTOSTERONE;

ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MORTALITY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; CYPROTERONE ACETATE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FRACTURES, BONE; GOSERELIN; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 78049530301     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70235-7     Document Type: Note

References (6)

1. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
2. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, published online Oct 7. 10.1016/S1470-2045(10)70223-0.
3. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 2009, 75:10-15.
4. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302:866-873.
5. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-108.
6. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.